CD19-Directed CAR-T Cell Therapy for B Cell Malignancies
This study is testing a treatment called IC19/1563, a type of CD19-directed CAR-T cell therapy, for people with B cell cancers that have returned or haven't responded to other treatments. CAR-T cell therapy uses your own immune cells (T cells) that are specially modified in a lab to recognize and fight cancer. Researchers want to find the highest safe dose of IC19/1563. You may be eligible if you are at least 18 years old and have certain types of relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The study aims to see how well IC19/1563 works and if it is safe. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 25 participants. It is designed to find the maximum tolerated dose of the IC19/1563 treatment.
- What's involved
- You would receive IC19/1563 given intravenously (IV) and may also receive Bendamustine (IV). You will undergo collection of blood and tissue samples, bone marrow aspiration, and bone marrow biopsy.
- Compensation
- Not stated in the trial record.
- Follow-up
- The maximum tolerated dose will be measured at 90 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT04892277
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Recruiting
PHASE1Ages 18+InterventionalTreatmentMayo ClinicInvestigator-initiated
~25 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563BendamustineBiospecimen CollectionBone Marrow AspirationBone Marrow BiopsyComputed Tomography
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum tolerated dose (MTD)
Measured over 90 days
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Saad J. Kenderian, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age \>= 18 years
Relapsed or refractory CD19+ B cell malignancies of the one of the following histopathology:
Biopsy proven B-cell non-Hodgkin lymphoma (NHL) of any histopathology (including Richter Transformation of CLL); relapsed or refractory disease defined as:
Two or more prior lines of therapy, at least one anthracycline containing regimen, unless intolerable. Exception: Patients with Richter transformation of CLL are eligible if they had \>= one prior treatment, including prior BTK inhibition
Demonstration of progressive or stable disease by positron emission tomography/computed tomography (PET/CT) or CT criteria as the best response to the most recent chemotherapy regimen according to the revised Lugano Response Criteria for Malignant Lymphoma.
Measurable disease defined as measurable by CT portion of a PET/CT: To be considered measurable, the must be at least one lesion that has a single diameter of (\>1.5 cm Note: Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
Biopsy proven SLL or flow cytometry proven CLL; relapsed disease defined as:
\>= two prior lines of therapy, and/or \>= 6 months of second line prior BTK inhibition (e.g. venetoclax and ibrutinib). Exception: Patients in stable disease (SD) or partial response (PR) with a known ibrutinib resistance mutation (BTK or phospholipase Cgamma2) may be included even if on ibrutinib therapy for less than 6 months.
Demonstration of progressive or stable disease by PET/CT or CT criteria according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL2018) criteria
Measurable disease by CT portion of a PET/CT where at least one lesion has a single diameter of \>1.5 cm or peripheral blood absolute blood lymphocyte count (ALC) of \> 5000. Note: Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Hemoglobin \>= 8.0 g/dL (=\< 14 days prior to registration)
Absolute neutrophil count (ANC) \>= 500/mm\^3 (=\< 14 days prior to registration)
Platelet count \>= 30,000/mm\^3 (=\< 14 days prior to registration)
Total bilirubin =\< 2.0 mg/dL (with the exception of subjects with Gilbert's syndrome. Subjects with Gilbert's syndrome may be included if their total bilirubin is =\< 3.0 x upper limit of normal (ULN) and direct bilirubin =\< 1.5 x ULN) (=\< 14 days prior to registration)
Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 3 x ULN (=\< 14 days prior to registration)
Prothrombin time (PT) / international normalized ratio (INR) and/or activated partial thromboplastin time (aPTT) =\< 1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy (for patients receiving anticoagulation, there should be no prior history of bleeding, and no recent deep venous thrombosis/pulmonary embolism (DVT/PE) within the last 6 months of enrollment) (=\< 14 days prior to registration)
Calculated creatinine clearance \>= 45 ml/min using the Cockcroft-Gault formula (=\< 14 days prior to registration)
Cardiac ejection fraction \>= 50% and no evidence of clinically significant pericardial effusion as determined by an echocardiogram (ECHO) or multigated acquisition scan (MUGA) scan
Baseline oxygen saturation \>= 92% on room air
Negative serum pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only
Women patients of child bearing potential, including women with tubal ligations, must commit to using use 2 highly effective forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives) for the duration of the study and for 12 months following IC19/1563 therapy
Provide written informed consent
Willingness to provide mandatory blood specimens for correlative research
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Exclusion
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
Pregnant persons
Nursing persons
Women of childbearing potential who are unwilling to employ highly effective contraception
Sexually active males who are not willing to use contraception during the study and for \>= 12 months after IC19/1563 therapy
Patients who are able to obtain market approved CD19 CAR T-cell therapies
Live vaccine =\< 6 weeks prior to start of registration
Autologous stem cell transplant =\< 6 weeks of registration
History of allogenic stem cell transplant if was performed less than 100 days prior to registration, if patients have active graft-versus host disease (GVHD) or are if patients are on chronic immunosuppression. Patients with allogeneic transplantation more than 100 days prior to registration, with no active GVHD and who are not on immunosuppression are eligible
History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
Any form of primary immunodeficiency such as severe combined immunodeficiency disease
Current need of systemic corticosteroid therapy, in doses over 20 mg /day of prednisone or equivalent forms of steroids
History of severe immediate hypersensitivity reaction to CART19, stem cell infusion dimethyl sulfoxide (DMSO) or any of the CAR-T cryopreservation ingredients
History of malignancy other than non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast) or early stage cancers (Stage I or II), unless disease free for \>= 2 years
Clinically significant active infection (e.g. simple urinary tract infection \[UTI\], bacterial pharyngitis allowed) or currently receiving IV antibiotics or have received IV antibiotics =\< 7 days prior to registration. Note: prophylactic antibiotics, antivirals and antifungals are permitted
Known history of human immunodeficiency virus (HIV) infection or acute or chronic hepatitis B or hepatitis C infection. Subjects with a history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines. Prophylactic antiviral therapy should be considered per institutional guidelines
History of any of the following cardiovascular conditions =\< 6 months:
Class III or IV heart failure as defined by the New York Heart Association (NYHA)
Cardiac angioplasty or stenting
Myocardial infarction
Unstable angina
Or other clinically significant cardiac disease
Any other acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or that, in the judgment of the investigator, would make the subject inappropriate for entry into the study
Concurrent cancer therapy. The following are exceptions:
Treatment with therapies may continue at time of registration; however, the washout period must be met prior to leukapheresis
Treatment with any other investigational agent may continue at time of registration provided last date of treatment is =\< 14 days prior to leukapheresis.
What this trial measures
- Maximum tolerated dose (MTD)90 days
MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients).